Back to Search
Start Over
Intravitreal anti-vascular endothelial growth factors, panretinal photocoagulation and combined treatment for proliferative diabetic retinopathy: a systematic review and network meta-analysis
- Publication Year :
- 2020
-
Abstract
- Purpose: to conduct a systematic review with network meta‐analysis (NMA) of randomized clinical trials (RCTs) comparing panretinal photocoagulation (PRP) versus anti‐vascular endothelial growth factor (VEGF) treatment alone or in combination with PRP, for proliferative diabetic retinopathy (PDR).Methods: PubMed, Medline and Embase databases were searched for RCTs comparing PRP versus intravitreal anti‐VEGF therapy and/or combined PRP and intravitreal anti‐VEGF for PDR. The primary outcome measures were the mean best corrected visual acuity (BCVA) change and the regression of neovascularization. Mean change of central macular thickness (CMT), the subgroup analyses of patients without diabetic macular oedema (DME) and the rate of vitreous haemorrhage and vitrectomy were secondary outcomes. Frequentist NMAs were performed.Results: twelve RCTs were included. For the 12‐month mean BCVA change, NMA showed a better visual outcome in both the anti‐VEGF group and combined group compared to PRP [anti‐VEGF vs PRP, mean difference (MD) = 3.42; standard error (SE) = 1.5; combined vs PRP, MD = 3.92; SE = 1.65], with no difference between combined group and anti‐VEGF (MD = −0.50; SE = 1.87). No difference in neovascularization regression was found between PRP and anti‐VEGF alone or in combination with PRP, but there was significant inconsistency (p = 0.016). Subgroup analyses in patients without DME yielded no difference for the 12‐month visual outcome between the three interventions, but with significant inconsistency (p = 0.005).Conclusion: this NMA showed limited evidence of comparable efficacy in terms of neovascularization regression between PRP and anti‐VEGF therapy alone or in combination with PRP, but better visual outcomes were associated with anti‐VEGF use. Intravitreal anti‐VEGF therapy could be a valid therapeutic option in association with PRP.
- Subjects :
- medicine.medical_specialty
Bevacizumab
genetic structures
pegaptanib
medicine.medical_treatment
Pegaptanib
Network Meta-Analysis
Visual Acuity
Vitrectomy
Angiogenesis Inhibitors
bevacizumab
law.invention
Neovascularization
03 medical and health sciences
0302 clinical medicine
Randomized controlled trial
aflibercept
intravitreal anti-VEGF
panretinal photocoagulation
proliferative diabetic retinopathy
ranibizumab
law
Ophthalmology
medicine
Humans
Aflibercept
Diabetic Retinopathy
Laser Coagulation
business.industry
General Medicine
Diabetic retinopathy
medicine.disease
eye diseases
Intravitreal Injections
030221 ophthalmology & optometry
sense organs
Ranibizumab
medicine.symptom
business
030217 neurology & neurosurgery
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....def1f0d3a40e21acdfa26f10e95c26ea